Table2.
Effect of Disulfiram on Antiretroviral Medication Pharmacokinetics
| A. Ritonavir (RTV) pharmacokinetics during disulfiram co-administration | ||||
|---|---|---|---|---|
| Parameter | RTV | RTV/DIS62.5 | RTV/DIS250 | p |
| AUCtau(h*ng/ml) | 9369 (978) | 10899 (1069) | 10960 (1343) | 0.715 |
| Clss/F (ml/h) | 22977 (1995) | 19992 (2020) | 20501 (2161) | 0.714 |
| Cmax (ng/ml) | 1399 (151) | 1669 (243) | 1758 (248) | 0.568 |
| Tmax (h) | 5.0 (1.5–6.0) | 4.0 (1.0–6.0) | 4.0 (2.0–6.0) | 0.332 |
| T1/2 (h) | 3.2 (0.5) | 2.9 (0.2) | 3.0 (0.3) | 0.798 |
| B. Atazanavir (ATV) pharmacokinetics during disulfiram co-administration | ||||
|---|---|---|---|---|
| Parameter | ATV | ATV/DIS62.5 | ATV/DIS250 | p |
| AUCtau(h*ng/ml) | 21895 (3407) | 25411 (3011) | 23127 (3030) | 0.698 |
| Clss/F (ml/h) | 23515 (4112) | 18586 (2867) | 21250 (3538) | 0.698 |
| Cmax (ng/ml) | 2823 (414) | 3602 (409) | 3571 (467) | 0.426 |
| Tmax (h) | 4.0 (1.5–6.0) | 2.0 (1.5–4.0) | 2.0 (1.5–4.0) | 0.342 |
| T1/2 (h) | 8.3 (1.1) | 7.8 (0.8) | 7.4(0.7) | 1.939 |
| C. favirenz (EFV) pharmacokinetics during disulfiram co–administration | ||||
|---|---|---|---|---|
| Parameter | EFV | EFV/DIS62.5 | EFV/DIS250 | p |
| AUCtau(h*µg/ml) | 166.5 (45.4) | 166.3 (57.6) | 234.9 (118.7) | 0.882 |
| Clss/F (l/h) | 10.4 (1.0) | 11.2 (1.1) | 11.3 (1.0) | 0.517 |
| Cmax (µg/ml) | 4.6 (0.5) | 4.8 (0.9) | 4.4 (0.5) | 0.983 |
| Tmax (h) | 4.0 (1.0–12.0) | 4.0 (2.0–8.0) | 4.0 (2.0–8.0) | 0.862 |
| T1/2 (h) | 29.3 (4.7) | 29.1 (4.7) | 29.3 (4.9) | 0.847 |
*
Note: Values are the mean (standard error of the mean) for 10 subjects who participated in the study in each group, except that the discontinuous variable, Tmax, is given as median (range).